Autologous dendritic-cell vaccine based on cancer-testis antigens “CaTeVac” in the treatment of soft tissue sarcoma

Pipia, Nino; Балдуева, Ирина; Nekhaeva, Tatyana; Novik, A.V. Novik; Данилова, Анна; Avdonkina, N.A.; Проценко, Светлана; Komarov, Yuriy; Girdyuk, D.V.; Oganesyan, Ani; Belyaеv, Alexey M.

doi:10.1093/annonc/mdy288.026

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data shows that patterns of CTA expression could be used for effective targeting of different histological types of tumors. Clinical data from our center support this evidence [49]. Advances from both rich allergenic material and autologous DC could be used for developing effective immunotherapeutic decisions.…”

Section: Discussionsupporting

confidence: 62%

Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells

Данилова¹,

Misyurin

Novik³

et al. 2020

Clin Sarcoma Res

View full text Add to dashboard Cite

Background: Autologous dendritic cells (DC) loaded with tumor-associated antigens (TAAs) are a promising approach for anticancer immunotherapy. Polyantigen lysates appear to be an excellent source of TAAs for loading onto the patient's dendritic cells. Cancer/testis antigens (CTA) are expressed by a wide range of tumors, but are minimally expressed on normal tissues, and could serve as a universal target for immunotherapy. However, CTA expression levels can vary significantly in patients with the same tumor type. We proposed that patients who do not respond to DC-based therapy may have distinct features of the CTA expression profile on tumor cells. Patients and methods: We compared the gene expression of the principal families CTA in 22 melanoma and 27 soft tissue and bone sarcomas cell lines (STBS), received from patients and used for DC vaccine preparation. Results: The majority (47 of 49, 95.9%) cell lines showed CTA gene activity. The incidence of gene expression of GAGE, NYESO1, MAGEA1, PRAME's was significantly different (adj. p < 0.05) between melanoma and sarcoma cell lines. The expression of the SCP1 gene was detected neither in melanoma cells nor in the STBS cells. Clustering by the gene expression profile revealed four different expression patterns. We found three main patterns types: hyperexpression of multiple CTA, hyperexpression of one CTA with almost no expression of others, and no expression of CTA. All clusters types exist in melanoma and sarcoma cell lines. We observed dependence of killing efficacy from the PRAME (rho = 0.940, adj. p < 0.01) expression during real-time monitoring with the xCELLigence system of the interaction between melanoma or sarcoma cells with the T-lymphocytes activated by the lysate of selected allogenous melanoma cell lines with high expression of CTA. Conclusion: Our results demonstrate that one can use lysates from allogeneic melanoma cell lines as a source of CTA for DC load during the production of anticancer vaccines for the STBS treatment. Patterns of CTA expression should be evaluated as biomarkers of response in prospective clinical trials.

show abstract

Section: Discussionsupporting

confidence: 62%

Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells

Данилова¹,

Misyurin

Novik³

et al. 2020

Clin Sarcoma Res

View full text Add to dashboard Cite

show abstract

“…Neoantigens such as cancer–testis antigens (CTA), aberrantly expressed in a high percentage of high-grade sarcoma, mainly MAGE and NY-ESO, as explained above in detail, might also be used to design personalized vaccines [ 32 ]. A phase I/II trial has evaluated an autologous dendritic-cell vaccine based on CTA (CaTeVac) in 74 patients with advanced STS, with a cohort receiving the vaccine as adjuvant or maintenance treatment after the first or second line of systemic therapy and another cohort receiving it in monotherapy after at least one CT line [ 116 ]. Median OS was 24.4 months in the first cohort and 14.2 months in the second one, suggesting a positive impact on overall survival.…”

Section: Immunotherapy For Sarcoma: Clinical Resultsmentioning

confidence: 99%

Current Landscape of Immunotherapy for Advanced Sarcoma

Albarrán

Villamayor

Pozas

et al. 2023

Cancers

View full text Add to dashboard Cite

There is substantial heterogeneity between different subtypes of sarcoma regarding their biological behavior and microenvironment, which impacts their responsiveness to immunotherapy. Alveolar soft-part sarcoma, synovial sarcoma and undifferentiated pleomorphic sarcoma show higher immunogenicity and better responses to checkpoint inhibitors. Combination strategies adding immunotherapy to chemotherapy and/or tyrosine–kinase inhibitors globally seem superior to single-agent schemes. Therapeutic vaccines and different forms of adoptive cell therapy, mainly engineered TCRs, CAR-T cells and TIL therapy, are emerging as new forms of immunotherapy for advanced solid tumors. Tumor lymphocytic infiltration and other prognostic and predictive biomarkers are under research.

show abstract

Clinical and immunological characteristics of sarcomas patients with clonogenic tumors

et al. 2021

View full text Add to dashboard Cite

Autologous dendritic-cell vaccine based on cancer-testis antigens “CaTeVac” in the treatment of soft tissue sarcoma

Cited by 3 publications

References 0 publications

Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells

Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells

Current Landscape of Immunotherapy for Advanced Sarcoma

Clinical and immunological characteristics of sarcomas patients with clonogenic tumors

Contact Info

Product

Resources

About